hydroxyurea has been researched along with Acute Disease in 88 studies
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of hydroxyurea for the prevention of sickle cell crises in patients with homozygous HbS disease is now well established." | 9.09 | Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. ( Kalotychou, V; Loukopoulos, D; Loutradi, A; Schina, M; Theodoropoulos, I; Voskaridou, E, 2000) |
| "To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia." | 7.75 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 7.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "An analysis of the risk of progression towards leukemia, carcinoma and myelofibrosis was performed in 93 patients treated by 32P alone (PVSG protocols) since 1970-1979, 395 patients over the age of 65 years treated by 32P with or without maintenance therapy using hydroxyurea (French protocol) since 1980-1994, and 202 patients under the age of 65 treated by either hydroxyurea or pipobroman since 1980." | 6.18 | Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". ( Dresch, C; Echard, M; Goguel, A; Grange, MJ; Lejeune, F; Najean, Y; Rain, JD, 1996) |
| "Hydroxyurea is an effective agent in the treatment of PV, but continued assessment of its mutagenic potential is necessary." | 5.27 | Treatment of polycythemia vera with hydroxyurea. ( Berk, PD; Donovan, PB; Goldberg, JD; Kaplan, ME; Knospe, WH; Laszlo, J; Mack, K; Najean, Y; Silberstein, EB; Tatarsky, I, 1984) |
| "We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis." | 5.09 | Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000) |
| "The use of hydroxyurea for the prevention of sickle cell crises in patients with homozygous HbS disease is now well established." | 5.09 | Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. ( Kalotychou, V; Loukopoulos, D; Loutradi, A; Schina, M; Theodoropoulos, I; Voskaridou, E, 2000) |
| " prevention of overwhelming bacterial infection, present indications and controversies regarding blood transfusion, prevention of stroke, acute chest syndrome, hydroxyurea therapy--probably the best disease modifying agent at the moment, stem cell transplantation--a cure and certain promising experimental therapies including gene therapy have been discussed in this review." | 4.82 | Advances in management of sickle cell disease. ( Agarwal, MB, 2003) |
| "To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia." | 3.75 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009) |
| "A young Arab woman with sickle cell-beta0-thalassemia disease developed acute colonic pseudo-obstruction that became chronic but showed some response to hydroxyurea." | 3.72 | Colonic pseudo-obstruction in sickle cell disease. ( Ayyaril, M; Daar, A; Knox-Macaulay, H; Nusrat, N, 2003) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 3.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "Hydroxyurea is increasingly being used to control myeloproliferative disorders, in part because of its relative lack of side effects." | 3.68 | Acute alveolitis induced by hydroxyurea in a patient with myeloproliferative syndrome. ( Andreesen, R; Bross, KJ; Hennemann, B; Reichle, A, 1993) |
| "Clinical complications of sickle cell anemia begin in infancy." | 2.77 | Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. ( Brown, RC; Casella, JF; Howard, TH; Iyer, RV; Lebensburger, JD; Lu, M; Miller, ST; Rogers, ZR; Sarnaik, S; Wang, WC, 2012) |
| "Calcitriol was continued as the only postremission therapy." | 2.67 | Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. ( Desforges, JF; Fogaren, T; Miller, KB; Slapak, CA, 1992) |
| "Hyperleukocytosis is defined as a white blood cell count greater than 100." | 2.58 | The management of hyperleukocytosis in 2017: Do we still need leukapheresis? ( Korkmaz, S, 2018) |
| "Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures." | 2.48 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012) |
| "Hyperleukocytosis, arbitrarily defined in acute leukemia as a white blood cell count greater than 100,000/mL, often is associated with increased morbidity and mortality in patients with leukemic processes." | 2.48 | Hyperleukocytosis, leukostasis and leukapheresis: practice management. ( Becker, J; Ganzel, C; Lazarus, HM; Mintz, PD; Rowe, JM, 2012) |
| "Sickle cell disease is a recessively inherited condition in which synthesis of haemoglobin is abnormal." | 2.41 | Acute complications of sickle cell disease in children. ( , 2001) |
| "Eight patients with M3 (acute promyelocytic leukemia) were excluded from the study." | 1.38 | Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients. ( Atkinson, HD; Colovic, M; Colovic, N; Jankovic, G; Kraguljac, N; Radojkovic, M; Stanisavljevic, D; Suvajdzic, N; Tomin, D; Vidovic, A, 2012) |
| " We conclude that valproic acid+ATRA+theophylline combined with 6-mercaptopurin or hydroxyurea can be safe and effective in palliative treatment of human AML." | 1.36 | Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases. ( Bruserud, Ø; Fredly, H; Gjertsen, BT; Stapnes Bjørnsen, C, 2010) |
| "State-of-art of aggressive treatment of acute myeloid leukemia (AML) in patients older than 60 years is one of the least satisfactory topics of present-day hematology." | 1.33 | Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy. ( Brychtova, Y; Buchtova, I; Doubek, M; Mayer, J; Palasek, I, 2005) |
| "Acute leukemia is an uncommon complication of patients with essential thrombocythemia (ET)." | 1.33 | Acute biphenotypic leukemia arising in a patient with essential thrombocythemia. ( Lee, LH; Wong, GC, 2006) |
| " Hydroxyurea at an increased dosage was effective in controlling the CML." | 1.32 | [Pure red cell aplasia occurring during the course of chronic myelogenous leukemia]. ( Kawauchi, K; Ogasawara, T; Ohkawa, S; Takei, K; Yasuyama, M, 2004) |
| "Hydroxyurea is a cytotoxic agent that is being increasingly used for a number of malignant and nonmalignant systemic diseases." | 1.29 | Hydroxyurea-induced acute interstitial lung disease. ( Gadsden, T; Gephardt, G; Kavuru, MS; Lichtin, A, 1994) |
| "Hydroxyurea is an effective agent in the treatment of PV, but continued assessment of its mutagenic potential is necessary." | 1.27 | Treatment of polycythemia vera with hydroxyurea. ( Berk, PD; Donovan, PB; Goldberg, JD; Kaplan, ME; Knospe, WH; Laszlo, J; Mack, K; Najean, Y; Silberstein, EB; Tatarsky, I, 1984) |
| "Hydroxyurea was administered orally to prevent the effects of leukostasis in adults with acute leukemia who had peripheral blast cell counts greater than 100,000/cu mm." | 1.26 | Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. ( Armitage, JO; Burns, P; Grund, FM, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (20.45) | 18.7374 |
| 1990's | 19 (21.59) | 18.2507 |
| 2000's | 31 (35.23) | 29.6817 |
| 2010's | 19 (21.59) | 24.3611 |
| 2020's | 1 (1.14) | 2.80 |
| Authors | Studies |
|---|---|
| Monus, T | 1 |
| Howell, CM | 1 |
| Janakiram, M | 1 |
| Verma, A | 1 |
| Wang, Y | 1 |
| Budhathoki, A | 1 |
| Suarez Londono, J | 1 |
| Murakhovskaya, I | 1 |
| Braunschweig, I | 1 |
| Minniti, CP | 1 |
| Özpolat, T | 1 |
| Kayar, Y | 1 |
| Sahutoglu, T | 1 |
| Korkmaz, S | 1 |
| Guilliams, KP | 1 |
| Fields, ME | 1 |
| Dowling, MM | 1 |
| Brousseau, DC | 1 |
| Richardson, T | 1 |
| Hall, M | 1 |
| Ellison, AM | 1 |
| Shah, SS | 1 |
| Raphael, JL | 1 |
| Bundy, DG | 1 |
| Arnold, S | 1 |
| Racho, RG | 1 |
| Krishna, M | 1 |
| Canabal, JM | 1 |
| Keaveny, AP | 1 |
| Patel, AB | 1 |
| Chen, YH | 1 |
| Zhang, Y | 1 |
| Frankfurt, O | 1 |
| Winter, JN | 1 |
| Badawy, SM | 1 |
| Shimazu, Y | 1 |
| Fujimura, K | 1 |
| Li, QB | 1 |
| Li, L | 1 |
| You, Y | 1 |
| Chen, ZC | 1 |
| Xia, LH | 1 |
| Zou, P | 1 |
| Beer, PA | 1 |
| Green, AR | 2 |
| Ballas, SK | 1 |
| Bauserman, RL | 1 |
| McCarthy, WF | 1 |
| Castro, OL | 1 |
| Smith, WR | 2 |
| Waclawiw, MA | 1 |
| Fredly, H | 1 |
| Stapnes Bjørnsen, C | 1 |
| Gjertsen, BT | 1 |
| Bruserud, Ø | 1 |
| Meremikwu, MM | 1 |
| Okomo, U | 1 |
| Lebensburger, JD | 1 |
| Miller, ST | 1 |
| Howard, TH | 1 |
| Casella, JF | 1 |
| Brown, RC | 1 |
| Lu, M | 1 |
| Iyer, RV | 1 |
| Sarnaik, S | 1 |
| Rogers, ZR | 2 |
| Wang, WC | 1 |
| Tefferi, A | 2 |
| Ganzel, C | 1 |
| Becker, J | 1 |
| Mintz, PD | 1 |
| Lazarus, HM | 1 |
| Rowe, JM | 1 |
| Colovic, M | 1 |
| Colovic, N | 1 |
| Radojkovic, M | 1 |
| Stanisavljevic, D | 1 |
| Kraguljac, N | 1 |
| Jankovic, G | 1 |
| Tomin, D | 1 |
| Suvajdzic, N | 1 |
| Vidovic, A | 1 |
| Atkinson, HD | 1 |
| Almeida, CB | 1 |
| Scheiermann, C | 1 |
| Jang, JE | 1 |
| Prophete, C | 1 |
| Costa, FF | 1 |
| Conran, N | 1 |
| Frenette, PS | 1 |
| Darbari, DS | 1 |
| Panepinto, JA | 1 |
| Matsui, WH | 1 |
| Gladstone, DE | 1 |
| Vala, MS | 1 |
| Barber, JP | 1 |
| Brodsky, RA | 1 |
| Smith, BD | 1 |
| Jones, RJ | 1 |
| Huang, PH | 1 |
| You, JY | 1 |
| Hsu, HC | 1 |
| Bernasconi, P | 1 |
| Boni, M | 1 |
| Cavigliano, PM | 1 |
| Calatroni, S | 1 |
| Brusamolino, E | 1 |
| Passamonti, F | 1 |
| Volpe, G | 1 |
| Pistorio, A | 1 |
| Giardini, I | 1 |
| Rocca, B | 1 |
| Caresana, M | 1 |
| Lazzarino, M | 1 |
| Bernasconi, C | 1 |
| Binder, WD | 1 |
| Brown, DF | 1 |
| Nadel, ES | 1 |
| Knox-Macaulay, H | 1 |
| Ayyaril, M | 1 |
| Nusrat, N | 1 |
| Daar, A | 1 |
| Nielsen, I | 1 |
| Hasselbalch, HC | 1 |
| Agarwal, MB | 1 |
| Yasuyama, M | 1 |
| Kawauchi, K | 1 |
| Takei, K | 1 |
| Ogasawara, T | 1 |
| Ohkawa, S | 1 |
| Barbui, T | 2 |
| Barosi, G | 1 |
| Grossi, A | 1 |
| Gugliotta, L | 1 |
| Liberato, LN | 1 |
| Marchetti, M | 1 |
| Mazzucconi, MG | 1 |
| Rodeghiero, F | 2 |
| Tura, S | 1 |
| Bakanay, SM | 1 |
| Dainer, E | 1 |
| Clair, B | 1 |
| Adekile, A | 1 |
| Daitch, L | 1 |
| Wells, L | 1 |
| Holley, L | 1 |
| Smith, D | 1 |
| Kutlar, A | 1 |
| Riccioni, R | 1 |
| Pasquini, L | 1 |
| Mariani, G | 1 |
| Saulle, E | 1 |
| Rossini, A | 1 |
| Diverio, D | 1 |
| Pelosi, E | 1 |
| Vitale, A | 1 |
| Chierichini, A | 1 |
| Cedrone, M | 1 |
| Foà, R | 1 |
| Lo Coco, F | 1 |
| Peschle, C | 1 |
| Testa, U | 1 |
| Zala, C | 1 |
| Salomón, H | 1 |
| Cahn, P | 1 |
| Doubek, M | 1 |
| Palasek, I | 1 |
| Brychtova, Y | 1 |
| Buchtova, I | 1 |
| Mayer, J | 1 |
| Perel, JM | 1 |
| McCarthy, C | 1 |
| Walker, O | 1 |
| Irving, I | 1 |
| Williams, B | 1 |
| Kennedy, GA | 1 |
| Wong, GC | 1 |
| Lee, LH | 1 |
| Quinn, CT | 1 |
| Shull, EP | 1 |
| Ahmad, N | 1 |
| Lee, NJ | 1 |
| Buchanan, GR | 1 |
| Burnett, AK | 1 |
| Milligan, D | 1 |
| Prentice, AG | 1 |
| Goldstone, AH | 1 |
| McMullin, MF | 1 |
| Hills, RK | 1 |
| Wheatley, K | 1 |
| Tubman, VN | 1 |
| Bennett, CM | 1 |
| Luo, HY | 1 |
| Chui, DH | 1 |
| Heeney, MM | 1 |
| Solomon, LR | 1 |
| Fawibe, AE | 1 |
| Donovan, PB | 2 |
| Kaplan, ME | 1 |
| Goldberg, JD | 2 |
| Tatarsky, I | 1 |
| Najean, Y | 2 |
| Silberstein, EB | 1 |
| Knospe, WH | 1 |
| Laszlo, J | 1 |
| Mack, K | 1 |
| Berk, PD | 2 |
| Paton, CM | 1 |
| Bishop, JF | 1 |
| Mathews, JD | 1 |
| Whiteside, MG | 1 |
| Biron, CA | 1 |
| Turgiss, LR | 1 |
| Welsh, RM | 1 |
| Passe, S | 1 |
| Miké, V | 1 |
| Mertelsmann, R | 1 |
| Gee, TS | 1 |
| Clarkson, BD | 1 |
| Barie, PS | 1 |
| Tahamont, MV | 1 |
| Malik, AB | 1 |
| Inhorn, RC | 1 |
| Aster, JC | 1 |
| Roach, SA | 1 |
| Slapak, CA | 2 |
| Soiffer, R | 1 |
| Tantravahi, R | 1 |
| Stone, RM | 1 |
| Kavuru, MS | 1 |
| Gadsden, T | 1 |
| Lichtin, A | 1 |
| Gephardt, G | 1 |
| Weinfeld, A | 1 |
| Swolin, B | 1 |
| Westin, J | 1 |
| Brincker, H | 1 |
| Christensen, BE | 1 |
| Boivin, P | 1 |
| Hennemann, B | 1 |
| Bross, KJ | 1 |
| Reichle, A | 1 |
| Andreesen, R | 1 |
| Furgerson, JL | 1 |
| Vukelja, SJ | 1 |
| Baker, WJ | 1 |
| O'Rourke, TJ | 1 |
| Friedman, HD | 1 |
| Landaw, SA | 2 |
| Nand, S | 2 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 2 |
| Rain, JD | 1 |
| Dresch, C | 1 |
| Goguel, A | 1 |
| Lejeune, F | 1 |
| Echard, M | 1 |
| Grange, MJ | 1 |
| Sánchez Fayos, J | 1 |
| Román Barbero, A | 1 |
| Nevado Reviriego, I | 1 |
| Cacciola, E | 1 |
| Cacciola, RR | 1 |
| Guglielmo, P | 1 |
| Stagno, F | 1 |
| Giustolisi, R | 1 |
| Randi, ML | 1 |
| Rossi, C | 1 |
| Fabris, F | 1 |
| Girolami, A | 1 |
| Yale, SH | 1 |
| Nagib, N | 1 |
| Guthrie, T | 1 |
| Finazzi, G | 1 |
| Ruggeri, M | 1 |
| Loukopoulos, D | 1 |
| Voskaridou, E | 1 |
| Kalotychou, V | 1 |
| Schina, M | 1 |
| Loutradi, A | 1 |
| Theodoropoulos, I | 1 |
| Longhurst, HJ | 1 |
| Pinching, AJ | 1 |
| Ferster, A | 1 |
| Tahriri, P | 1 |
| Vermylen, C | 1 |
| Sturbois, G | 1 |
| Corazza, F | 1 |
| Fondu, P | 1 |
| Devalck, C | 1 |
| Dresse, MF | 1 |
| Feremans, W | 1 |
| Hunninck, K | 1 |
| Toppet, M | 1 |
| Philippet, P | 1 |
| Van Geet, C | 1 |
| Sariban, E | 1 |
| Montefusco, E | 1 |
| Fazi, F | 1 |
| Cordone, I | 1 |
| Ariola, C | 1 |
| Nanni, M | 1 |
| Spadea, A | 1 |
| Spiriti, MA | 1 |
| Fenu, S | 1 |
| Mandelli, F | 1 |
| Petti, MC | 1 |
| Bégué, P | 1 |
| Castello-Herbreteau, B | 1 |
| Bauer, HI | 1 |
| Kaatz, M | 1 |
| Elsner, P | 1 |
| Grund, FM | 1 |
| Armitage, JO | 1 |
| Burns, P | 1 |
| Berg, J | 1 |
| Vincent, PC | 4 |
| Gunz, FW | 5 |
| Berkman, EM | 1 |
| Caplan, SN | 1 |
| Tokumaru, T | 1 |
| Wilentz, J | 1 |
| Desforges, JF | 1 |
| Fogaren, T | 1 |
| Miller, KB | 1 |
| Liang, R | 1 |
| Chan, TK | 1 |
| Chiu, E | 1 |
| Todd, D | 1 |
| van den Anker-Lugtenburg, PJ | 1 |
| Sizoo, W | 1 |
| Messmore, H | 1 |
| Bird, ML | 1 |
| Schulz, W | 1 |
| Fisher, RI | 1 |
| Osterwalder, B | 1 |
| Schmid, L | 1 |
| Jungi, WF | 1 |
| Flury, R | 1 |
| Schmid, U | 1 |
| Staub, P | 1 |
| Senn, HJ | 1 |
| Fruchtman, SM | 1 |
| Berlin, NI | 1 |
| Wasserman, LR | 1 |
| Slocombe, RF | 1 |
| Malark, J | 1 |
| Ingersoll, R | 1 |
| Derksen, FJ | 1 |
| Robinson, NE | 1 |
| Levi, JA | 3 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)[NCT00006400] | Phase 3 | 193 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| Sickle Cell Disease (SCD) Biochip': Towards a Simple and Reliable Way to Monitor Sickle Cell Disease[NCT02824471] | 100 participants (Anticipated) | Observational | 2014-10-31 | Recruiting | |||
| Comparison of Sub-dissociative Intranasal Ketamine Plus Standard Pain Therapy Versus Standard Pain Therapy in the Treatment of Pediatric Sickle Cell Disease Vasoocclusive Crises in Resource-limited Settings: a Multi-centered, Randomized, Controlled Trial[NCT02573714] | 160 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| Quantitative and Prognostic Evaluation of Dense Red Blood Cells in Sickle Cell Children: Single-center Study From the Creteil (France) Pediatric Cohort[NCT02887118] | 82 participants (Actual) | Observational | 2015-12-31 | Terminated (stopped due to The recruiting centre was no longer presenting new patients for inclusion) | |||
| A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over[NCT00005823] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1998-12-31 | Completed | ||
| A Phase I-II, Multicentre, Open Label Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine, Plus Venetoclax and Quizartinib in Newly Diagnosed Acute Myeloid Leukemia Patients Aged Equal or More Than[NCT04687761] | Phase 1/Phase 2 | 84 participants (Anticipated) | Interventional | 2020-11-04 | Recruiting | ||
| The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients[NCT01633099] | Phase 3 | 46 participants (Anticipated) | Interventional | 2012-05-31 | Active, not recruiting | ||
| Single-center Prospective Evaluation of Sickle Cell Patient Care in the CHU Brugmann Emergency Department[NCT02386657] | 104 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| Multicenter Phase 2 Study of Efficacy and Safety of Pegylated Interferon-alfa 2a in Polycythemia Vera Patients[NCT00241241] | Phase 2 | 40 participants | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded). (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 22.56 |
| Placebo | 20.74 |
GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 10.57 |
| Placebo | 14.33 |
Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 28.65 |
| Placebo | 33.36 |
19 reviews available for hydroxyurea and Acute Disease
| Article | Year |
|---|---|
Current and emerging treatments for sickle cell disease.
Topics: Acute Chest Syndrome; Acute Disease; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Bacterial Agents; | 2019 |
The management of hyperleukocytosis in 2017: Do we still need leukapheresis?
Topics: Acute Disease; Female; Humans; Hydroxyurea; Induction Chemotherapy; Leukapheresis; Leukemia; Leukocy | 2018 |
Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease.
Topics: Acute Disease; Anemia, Sickle Cell; Blood Transfusion; Brain Ischemia; Cerebral Arteries; Cerebrovas | 2019 |
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyu | 2009 |
Sickle cell disease.
Topics: Acute Disease; Analgesia, Patient-Controlled; Anemia, Sickle Cell; Blood Transfusion; Humans; Hydrox | 2011 |
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management | 2012 |
Hyperleukocytosis, leukostasis and leukapheresis: practice management.
Topics: Acute Disease; Humans; Hydroxyurea; Induction Chemotherapy; Leukapheresis; Leukemia; Leukocyte Count | 2012 |
What is the evidence that hydroxyurea improves health-related quality of life in patients with sickle cell disease?
Topics: Acute Disease; Adult; Affect; Anemia, Sickle Cell; Child; Cognitive Behavioral Therapy; Cohort Studi | 2012 |
Advances in management of sickle cell disease.
Topics: Acute Disease; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Bacterial Infections; Blood Tra | 2003 |
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Cell Transformation, Neoplastic; Child; Clinical Tria | 2004 |
Managing acute chest syndrome of sickle cell disease in an African setting.
Topics: Acute Disease; Anemia, Sickle Cell; Antisickling Agents; Diagnosis, Differential; Humans; Hydroxyure | 2008 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1995 |
Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection.
Topics: Acute Disease; Aged; Allopurinol; Anemia, Refractory; Anti-Bacterial Agents; Biopsy; Blood Cell Coun | 1996 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
[Efficacious treatment of a fatal blood disease: polycythemia vera].
Topics: Acute Disease; Alkylating Agents; Busulfan; Chlorambucil; Humans; Hydroxyurea; Leukemia, Myeloid; Le | 1997 |
Approach to the vaso-occlusive crisis in adults with sickle cell disease.
Topics: Acute Disease; Adult; Analgesics; Analgesics, Opioid; Anemia, Sickle Cell; Antisickling Agents; Arte | 2000 |
The pathogenesis and management of essential thrombocythaemia.
Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; He | 1999 |
Acute complications of sickle cell disease in children.
Topics: Abdominal Pain; Acute Disease; Adolescent; Analgesics; Anemia, Aplastic; Anemia, Sickle Cell; Animal | 2001 |
[Sickle cell disease: from childhood to adolescence. Management in 2001].
Topics: Acute Disease; Adolescent; Anemia, Sickle Cell; Bacterial Infections; Child; Humans; Hydroxyurea; In | 2001 |
10 trials available for hydroxyurea and Acute Disease
60 other studies available for hydroxyurea and Acute Disease
| Article | Year |
|---|---|
Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.
Topics: Acute Disease; Adult; Anemia, Sickle Cell; Antineoplastic Agents; Cell Transformation, Neoplastic; F | 2018 |
Acute renal infarction: a presentation of essential thrombocytosis.
Topics: Acute Disease; Adult; Anticoagulants; Biopsy; Bone Marrow; Contrast Media; Female; Glomerular Filtra | 2017 |
Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.
Topics: Acute Disease; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cross- | 2019 |
Liver Transplantation for Acute Liver Failure Secondary to Acute Sickle Intrahepatic Cholestasis.
Topics: Acute Disease; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Bradycardia; Budd-Chiari | 2020 |
Achievement of morphologic and cytogenetic remission with single-agent hydroxyurea in a patient with acute myeloid leukemia with inv(16).
Topics: Acute Disease; Antineoplastic Agents; Chromosome Inversion; Core Binding Factor beta Subunit; Gene O | 2015 |
The Use of Hydroxyurea and Leukapheresis in Childhood Acute Leukemia With Hyperleukocytosis.
Topics: Acute Disease; Child; Humans; Hydroxyurea; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis | 2016 |
Acute pancreatitis as a side effect of anagrelide hydrochloride hydrate: a case report.
Topics: Abdominal Pain; Acute Disease; Aged; Aspirin; Drug Substitution; Female; Humans; Hydroxyurea; Janus | 2016 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combine | 2009 |
Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex, age, and geographical location.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Analgesics, Non-Narcotic; Anemia, Sickle Cell; Climat | 2010 |
Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Hist | 2010 |
Pain in sickle cell disease: the future of acute treatment.
Topics: Acute Disease; Anemia, Sickle Cell; Biomarkers; Humans; Hydroxyurea; Pain; Vascular Diseases | 2011 |
Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Compon | 2012 |
Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acute Disease; Anemia, Sickle Cell; Animals; Antisickling Agent | 2012 |
The role of growth factors in the activity of pharmacological differentiation agents.
Topics: Acute Disease; Antigens, CD; Antineoplastic Agents; Apoptosis; Bryostatins; Cell Cycle; Cell Differe | 2002 |
Extensive pulmonary infiltration by leukemic blasts successfully treated with hydroxyurea--a case report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Blast Crisis; Diagnosis, Differential; Humans; Hydroxyu | 2002 |
Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Female; Humans; H | 2002 |
Blurred vision, epistaxis, and fever in a young man.
Topics: Acute Disease; Adult; Allopurinol; Antimetabolites; Antineoplastic Agents; Epistaxis; Fever; Fluid T | 2002 |
Colonic pseudo-obstruction in sickle cell disease.
Topics: Acute Disease; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Colonic Pseudo-Obs | 2003 |
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma | 2003 |
[Pure red cell aplasia occurring during the course of chronic myelogenous leukemia].
Topics: Acute Disease; Antineoplastic Agents; Blood Transfusion; Cyclosporine; Hepatitis C; Humans; Hydroxyu | 2004 |
Mortality in sickle cell patients on hydroxyurea therapy.
Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hy | 2005 |
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Diffe | 2005 |
Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
Topics: Acute Disease; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Enzyme | 1999 |
Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2005 |
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamid | 2005 |
Acute biphenotypic leukemia arising in a patient with essential thrombocythemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, | 2006 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Sickle cell disease caused by Hb S/Québec-CHORI: treatment with hydroxyurea and response.
Topics: Abdominal Pain; Acute Disease; Anemia, Sickle Cell; Cholecystectomy; Cholecystitis; Exchange Transfu | 2007 |
Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void.
Topics: Acute Disease; Analgesics, Opioid; Anemia, Sickle Cell; Clinical Competence; Humans; Hydroxyurea; Op | 2008 |
Treatment of polycythemia vera with hydroxyurea.
Topics: Acute Disease; Aged; Bone Marrow; Female; Humans; Hydroxyurea; Leukemia; Leukopenia; Male; Middle Ag | 1984 |
Increase in NK cell number and turnover rate during acute viral infection.
Topics: Acute Disease; Animals; Cell Count; Cell Cycle; Cell Separation; Centrifugation, Density Gradient; D | 1983 |
Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined | 1982 |
Prevention of increased pulmonary vascular permeability after pancreatitis by granulocyte depletion in sheep.
Topics: Acute Disease; Animals; Capillary Permeability; Granulocytes; Hydroxyurea; Lung; Lymphatic System; M | 1982 |
Hydroxyurea-induced acute interstitial lung disease.
Topics: Acute Disease; Aged; Biopsy; Female; Humans; Hydroxyurea; Lung; Lung Diseases, Interstitial; Prednis | 1994 |
Acute mucocutaneous toxicity following high-dose hydroxyurea.
Topics: Acute Disease; Adult; Drug Eruptions; Humans; Hydroxyurea; Male; Stomatitis | 1993 |
Acute alveolitis induced by hydroxyurea in a patient with myeloproliferative syndrome.
Topics: Acute Disease; Aged; Alveolitis, Extrinsic Allergic; Humans; Hydroxyurea; Male; Myeloproliferative D | 1993 |
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.
Topics: Acute Disease; Antineoplastic Agents; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Thr | 1996 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea.
Topics: Acute Disease; Antisickling Agents; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Polyc | 1999 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
Drug Points: pancreatitis associated with hydroxyurea in combination with didanosine.
Topics: Acute Disease; Adult; Anti-HIV Agents; Didanosine; Drug Combinations; HIV Infections; Humans; Hydrox | 2001 |
Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Anemia, Sickle Cell; Antisickling Agents; Arteri | 2001 |
Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Leuk | 2001 |
[Circumscribed hypertrichosis lanuginosa in acute myeloid leukemia].
Topics: Acute Disease; Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Fatal Outcome; Humans; Hydroxyurea; | 2001 |
Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Blood Cells; Female; Humans; Hydroxyurea; Leukemia, Lymphoid | 1977 |
Extreme leucocytosis and prognosis of newly diagnosed patients with acute non-lymphocytic leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Hu | 1979 |
Engraftment of RH-positive marrow in a recipient with RH antibody.
Topics: Acute Disease; Adult; Blood Group Incompatibility; Bone Marrow Cells; Bone Marrow Transplantation; C | 1977 |
The place of research in hospital medicine.
Topics: Acute Disease; Australia; Cell Division; History, 20th Century; Hospital Administration; Hospitals, | 1975 |
Iridoplegia and aqueous flare due to acute herpetic keratouveitis.
Topics: Acute Disease; Animals; Aqueous Humor; Dactinomycin; Eye Diseases; Eye Proteins; Hydroxyurea; Iris; | 1975 |
Non-aggressive therapy for chronic myeloid leukaemia in blastic transformation.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1992 |
Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
Topics: Acute Disease; Female; Humans; Hydroxyurea; Leukemia; Middle Aged; Myelodysplastic Syndromes; Thromb | 1990 |
Leukemic transformation in polycythemia vera: analysis of risk factors.
Topics: Acute Disease; Female; Humans; Hydroxyurea; Leukemia; Male; Middle Aged; Polycythemia Vera; Retrospe | 1990 |
[Myeloproliferative syndrome and acute febrile neutrophilic dermatosis (Sweet's syndrome)--a rare association].
Topics: Acute Disease; Adrenal Cortex Hormones; Aged; Fever; Humans; Hydroxyurea; Male; Myeloproliferative D | 1987 |
Acute leukemia in polycythemia vera.
Topics: Acute Disease; Antigens, Neoplasm; Bloodletting; Chlorambucil; Chromosome Aberrations; Chromosome Di | 1986 |
Importance of neutrophils in the pathogenesis of acute pneumonic pasteurellosis in calves.
Topics: Acute Disease; Animals; Cattle; Cattle Diseases; Hydroxyurea; Leukocyte Count; Male; Neutrophils; Pa | 1985 |
Combination chemotherapy of adult acute nonlymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Bone Marrow; Cytarabine; Drug Synergism; Female; Humans; Hyd | 1972 |
The outlook for the adult with acute leukaemia, 1972.
Topics: Acute Disease; Adolescent; Adult; Aged; Bacterial Infections; Cytarabine; Drug Combinations; Female; | 1972 |
Optimism in leukemia treatment.
Topics: Acute Disease; Adult; Child; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; Leukemia, | 1973 |
Proceedings: Treatment of acute leukaemia in adults.
Topics: Acute Disease; Adult; Allopurinol; Anti-Bacterial Agents; Bacterial Infections; Child; Cytarabine; D | 1974 |